Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

NCT06041620 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Thalassemia, Beta
Thalassemia Major

Interventions

BIOLOGICAL: VGB-Ex01

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]